Biotech China 2014
15th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma
The Fairmont Château Whistler
4599 Château Blvd.
Whistler, British Columbia
http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/592
   Deadlines
   ---------

     *  Abstract Deadline:
       14th January 2011


   Speakers
   --------

   Andrew D. Zelenetz,
   John C. Byrd,
   Sundar Jagannath,
   John P. Leonard,
   Charles Schiffer,
   Tracy Batchelor,
   Jennifer R. Brown,
   Joseph M. Connors,
   Carlo M. Croce,
   Daniel J. DeAngelo,
   Harry Erba,
   Richard I. Fisher,
   Randy D. Gascoyne,
   Steven M. Horwitz,
   Jean-Pierre Issa,
   Ross L. Levine,
   Sagar Lonial,
   Ruben A. Mesa,
   Natarajan Muthusamy,
   Jerald P. Radich,
   Noopur Raje,
   Donna Reece,
   Laurie H. Sehn,
   Sonali M. Smith,
   David Steensma,
   Keith Stewart,
   Martin S. Tallman,
   James C. Wade,
   William G. Wierda,
   Wyndham H. Wilson,
   Anas Younes,
   Jeffrey Zonder

   Overview and Purpose
   The purpose of the 15th Annual International Congress on Hematologic
   Malignancies: Focus on Leukemias, Lymphomas, and Myeloma , a part of
   the PER curriculum on hematologic malignancies, is to provide a unique
   opportunity for physicians to learn from and interact with
   international leaders in order to increase knowledge, apply new data
   to practice, and improve therapy and supportive care for patients with
   leukemia, lymphoma, and myeloma. This annual program is designed to
   facilitate integration of evolving and contemporary standards of care
   for the optimal treatment of patients with hematologic malignancies
   into community oncologists’ practice. To maximize learning, a variety
   of formats will be employed, including “How I Manage� expert
   approaches, multidisciplinary tumor boards, debates, panel
   discussions, and didactic lectures. In addition to reviewing standards
   of care, translational workshops will provide insight into
   next-generation therapeutic strategies.

   Target Audience This educational program is directed toward medical
   oncologists and hematologists interested in the treatment of patients
   with hematologic malignancies. Fellows, nurse practitioners, nurses,
   physician assistants, pharmacists, researchers, and other health care
   professionals interested in the treatment of hematologic malignancies
   are also invited to attend. Learning Objectives At the conclusion of
   this congress, you should be able to: Outline contemporary prognostic
   markers and optimal response-monitoring strategies applicable to
   treating patients with hematologic malignancies Discuss emerging data
   and recent advances in the treatment of patients with newly diagnosed
   hematologic malignancies and integrate key findings into clinical
   practice Compare and contrast the benefits of current and emerging
   hematopoietic stem cell transplantation strategies in leukemia,
   lymphoma, and myeloma and integrate key findings into clinical
   practice Debate the benefits of maintenance therapies in patients with
   leukemia, lymphoma, and myeloma and integrate key findings into
   clinical practice Evaluate the safety and efficacy of recent clinical
   advances in the management of patients with relapsed/refractory
   leukemia, lymphoma, and myeloma and integrate key findings into
   clinical practice Evaluate emerging novel agents for the treatment of
   patients with hematologic malignanci


   4599 Château Blvd., Whistler, British Columbia, V0N 1B4 , Canada

   Loading (May not complete on browsers without Javascript support)...

   Try again

Schedule of Presentations:

Thursday, February 17, 2011
06:00:00 Registration
06:15:00 Continental Breakfast | Meet and Consult Professors on Challenging Cases
06:55:00 Welcome Andrew D. Zelenetz, MD, PhD
07:00:00 Lymphoma John P. Leonard
07:05:00 Introductions and Presession Survey
07:15:00 Maintenance Therapy in Follicular Lymphoma Richard I. Fisher
07:30:00 Comment John P. Leonard
07:35:00 My Approach to Initial Management of Marginal Zone Lymphoma John P. Leonard
07:45:00 Comment Wyndham H. Wilson
07:50:00 DEBATE | Should we focus on overall survival or progression-free survival in follicular lymphoma?
07:55:00 Overall Survival Andrew D. Zelenetz, MD, PhD
08:10:00 Progression-Free Survival Richard I. Fisher
08:25:00 Question-and-Answer Session
08:35:00 Toward Optimal Initial Management of Mantle Cell Lymphoma Wyndham H. Wilson
08:50:00 Comment Laurie H. Sehn
08:55:00 My Approach to Initial Management of Diffuse Large B-Cell Lymphoma Laurie H. Sehn
09:10:00 Comment Joseph M. Connors
09:15:00 Controversies in Hodgkin Lymphoma Joseph M. Connors
09:30:00 Comment Steven Horwitz
09:35:00 Do New Therapies Change the Paradigm for Treatment of Peripheral T-Cell Lymphoma? Steven Horwitz
09:50:00 Comment John P. Leonard
09:55:00 Primary Central Nervous System Lymphoma Tracy T Batchelor
10:10:00 Question-and-Answer Session Postsession Survey
10:15:00 Break
10:25:00 Lymphoma Cases and Chronic Lymphocytic Leukemia John C. Byrd
10:30:00 Panel Discussion | Lymphoma Cases
11:30:00 How I Manage Frontline Chronic Lymphocytic Leukemia John C. Byrd
11:45:00 Comment William G. Wierda
11:50:00 How I Manage Relapsed/Refractory Chronic Lymphocytic Leukemia William G. Wierda
12:05:00 Comment Jennifer R. Brown
12:10:00 Management of Autoimmune Issues in Chronic Lymphocytic Leukemia Jennifer R. Brown
12:25:00 Comment John C. Byrd
12:30:00 Question-and-Answer Session
12:40:00 Adjourn
13:55:00 Afternoon Workshop | Signaling Inhibitors Carlo M Croce
14:00:00 JAK2 Inhibitors Ross L. Levine
14:20:00 BCR | Downstream Therapeutic Targets Jennifer R. Brown
14:40:00 New Tyrosine Kinase and Signaling Inhibitors in CML Richard Van Etten
15:00:00 mTOR Inhibitors Sonali M. Smith
15:20:00 PI3K | Akt Pathway Inhibitors Jennifer R. Brown
15:40:00 CDK Inhibitors Noopur Raje
16:00:00 Adjourn
18:30:00 Welcome Reception
Friday, February 18, 2011
06:15:00 Continental Breakfast | Meet and Consult Professors on Challenging Cases
06:55:00 Multiple Myeloma
07:00:00 Welcome and Introductions Sundar Jagannath
07:05:00 Presession Survey
07:15:00 Highlights in the Management of Elderly Patients With Newly Diagnosed Myeloma Sagar Lonial
07:30:00 Highlights in the Management of Transplantation-Eligible Patients With Newly Diagnosed Myeloma Donna Reece
07:40:00 DEBATE | Should all patients with myeloma receive maintenance therapy?
07:45:00 PRO Sundar Jagannath
08:00:00 CON Keith Stewart
08:15:00 Question-and-Answer Session
08:25:00 Highlights in the Management of Patients With Myeloma Relapsing After 1-3 Prior Therapies Jeffery Zonder
08:40:00 Promising New Drugs in Clinical Trials in Myeloma Keith Stewart
08:55:00 Update from the 6th International Workshop on the Biology and Therapy of Waldenstrom's Macroglobulinemia Steven P. Treon
09:15:00 Panel Discussion | Myeloma Cases
10:05:00 Question-and-Answer Session Postsession Survey
10:15:00 Break
10:25:00 Myeloproliferative Neoplasms Martin S. Tallman
10:30:00 Keynote Lecture | Overview of Molecular Pathways in Myeloproliferative Diseases Ross L. Levine
11:00:00 How I Treat Newly Diagnosed Chronic Myeloid Leukemia Charles Schiffer
11:15:00 Comment Jerald P. Radich
11:20:00 How I Treat Myelofibrosis If No Clinical Trial Is Available Ruben A Mesa
11:35:00 Comment Elihu H. Estey
11:40:00 Question-and-Answer Session
11:45:00 Perspectives on the Challenges of Clinical Trials James C. Wade, Charles Schiffer, Elihu H. Estey
12:45:00 Adjourn
13:55:00 Afternoon Workshop | Epigenetics and Gene Expression Anas Younes
14:00:00 Epigenetics and the Biology of Hematologic Malignancies Anas Younes
14:20:00 HDAC Function and HDAC Inhibitors: Where Is the Selectivity? Jean-Pierre Issa
14:40:00 MicroRNA and the Biology of Hematologic Malignancies Carlo M Croce
15:00:00 HDAC Inhibitors in Phase III Clinical Trials Sundar Jagannath
15:20:00 Epigenetic Targeting of NF-κB in Lymphoid Malignancies John C. Byrd
15:40:00 Genomics and Its Clinical Relevancy Randy D. Gascoyne
16:00:00 Adjourn
Saturday, February 19, 2011
06:15:00 Continental Breakfast | Meet and Consult Professors on Challenging Cases
06:55:00 Acute Leukemias and Myelodysplastic Syndromes Moderator Charles Schiffer
07:00:00 Welcome and Introductions
07:05:00 Presession Survey
07:15:00 How I Manage Acute Myeloid Leukemia in Elderly Patients Harry Erba
07:35:00 Comment David Steensma
07:40:00 How I Manage Low-Risk Myelodysplastic Syndromes David Steensma
08:00:00 Comment Jean-Pierre Issa
08:05:00 Can Acute Promyelocytic Leukemia Be Managed Without Chemotherapy? Martin S. Tallman
08:25:00 Comment Charles Schiffer
08:30:00 Panel Discussion | Myeloid Malignancy Cases
08:55:00 DEBATE | Molecular characterization of acute myeloid leukemia is of value in guiding therapy
09:00:00 PRO Jerald P. Radich
09:15:00 CON Harry Erba
09:30:00 Question-and-Answer Session
09:40:00 Aggressive Lymphoid Malignancies (Acute Lymphoblastic Leukemia, Lymphoblastic Leukemia, Burkitt Lymphoma) Daniel J. DeAngelo
10:00:00 Comment
10:05:00 Question-and-Answer Session Postsession Survey
10:15:00 Break
10:25:00 Supportive Care in Hematologic Malignancies Andrew D. Zelenetz, MD, PhD
10:30:00 Cord Blood and Haploidentical Stem Cells | An Expanding Opportunity in Allogeneic Stem Cell Transplantation?
10:55:00 Question-and-Answer Session
11:05:00 Outlook for Management of Bone Disease in Multiple Myeloma Noopur Raje
11:30:00 Question-and-Answer Session
11:40:00 Infectious Complications in Hematologic Malignancies James C. Wade
12:05:00 Question-and-Answer Session
12:15:00 Management of Thrombocytopenia Charles Schiffer
12:40:00 Question-and-Answer Session
12:45:00 Adjourn
13:55:00 Afternoon Workshop | Monoclonal Antibodies Andrew D. Zelenetz, MD, PhD
14:00:00 Therapeutic Antibodies | A Decade of Design Natarajan Muthusamy
14:20:00 MoAbs in Hodgkin Lymphoma: Antibody-Drug Conjugates Joseph M. Connors
14:40:00 MoAbs in Multiple Myeloma Sagar Lonial
15:00:00 Non-Hodgkin Lymphoma: Conjugated and Nonconjugated MoAbs Anas Younes
15:20:00 The Nature of Future MoAbs in Leukemia William G. Wierda
15:40:00 Clinical Development of MoAbs | Lessons Learned
16:00:00 Adjourn
Sunday, February 20, 2011
06:30:00 Continental Breakfast
06:55:00 Tumor Boards | Challenging Cases in Hematologic Malignancies and Attendee-Submitted Cases Andrew David Zelenetz
07:00:00 Acute Myeloid Leukemia | Myelodysplastic Syndromes Jean-Pierre Issa, Daniel J. DeAngelo, Harry Erba
07:30:00 Chronic Myeloid Leukemia | Myeloproliferative Neoplasms Richard Van Etten, Ross L. Levine, Jerald P. Radich, Elihu H. Estey, Ruben A Mesa
08:00:00 Chronic Lymphocytic Leukemia Andrew D. Zelenetz, MD, PhD, William G. Wierda, John C. Byrd
08:30:00 Lymphoma Wyndham H. Wilson, Steven Horwitz, Joseph M. Connors, Randy D. Gascoyne
09:00:00 Multiple Myeloma Jeffery Zonder, Keith Stewart, Donna Reece, Noopur Raje, Sagar Lonial, Sundar Jagannath
09:30:00 Adjourn
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.